Search

Zentalis Pharmaceuticals Inc

Lezárt

3.71 -0.54

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.65

Maximum

3.79

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+132.37% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

25M

356M

Előző nyitás

4.25

Előző zárás

3.71

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 31. 23:56 UTC

News

Array Technologies has acquired Affordable Wire Management, enhancing its portfolio and growth potential. Shares are trading slightly higher in after-market hours.

2026. aug. 31. 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

2026. aug. 31. 23:56 UTC

Correlated Moves

Regal Rexnord Corp shares are higher in after-market trading, reflecting a cumulative return of 0.44% since Monday's close amid similar trends from Eaton Corporation PLC.

2026. aug. 31. 23:56 UTC

Schrodinger Inc shares are higher in after-hours trading, influenced by rising oil prices and inflation concerns ahead of the Federal Reserve meeting.

2026. aug. 31. 23:56 UTC

Mosaic Co's shares are lower in after-market hours, reflecting inflation concerns from rising oil prices ahead of the Federal Reserve meeting.

2026. aug. 31. 23:56 UTC

TransDigm Group Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid overall weak market performance.

2026. aug. 31. 23:56 UTC

News

Frontier Group Holdings plans to terminate leases for 13 A320neo aircraft, leading to anticipated charges of $60 million to $80 million. Shares are lower in after-market hours.

2026. aug. 31. 23:56 UTC

Exelon Corp shares are lower in after-market trading, following fluctuations since Monday's close. Rising oil prices and inflation concerns influence broader market sentiment.

2026. aug. 31. 23:56 UTC

Shell PLC shares are lower in after-market trading, following a slight decline since Monday's close. Oil prices have risen, impacting broader market sentiment.

2026. aug. 31. 23:56 UTC

abrdn Physical Palladium Shares ETF traded roughly flat after-market hours, with no specific news identified. Global equity indices are mixed amid inflation concerns.

2026. aug. 31. 23:52 UTC

Japan's Q2 2026 Capital Spending YoY forecasted to rise only 0.2%, signaling subdued private investment growth amid cautious market sentiment.

2026. aug. 31. 23:52 UTC

South Korea's S&P Global Manufacturing PMI release on September 1 faces cautious market sentiment amid rising oil prices and inflation concerns.

2026. aug. 31. 23:52 UTC

Federal Reserve Chair Kevin Warsh's hawkish remarks boost interest rate hike expectations to 60-65% amid rising inflation concerns and geopolitical tensions.

2026. aug. 31. 23:52 UTC

ISM Manufacturing Employment Data Release on September 1, 2026, Sparks Caution Amid Inflation Concerns and Fed Rate Hike Speculation.

2026. aug. 31. 23:52 UTC

ISM Manufacturing PMI Release on September 1 Expected to Show Continued Growth Amid Geopolitical Tensions and Fed Rate Hike Speculation.

2026. aug. 31. 23:52 UTC

Australia's Balance of Trade data set for September 3, 2026, anticipates a AUD 1.4 billion surplus amid mixed market sentiment and geopolitical tensions affecting investor confidence.

2026. aug. 31. 23:52 UTC

JOLTs Job Openings Report on September 1 Expected to Influence Fed Rate Hike Decisions Amid Geopolitical Tensions and Inflation Concerns.

2026. aug. 31. 23:52 UTC

U.S. Initial Jobless Claims Expected at 205K Amid Inflation Concerns and Fed Rate Hike Speculation

2026. aug. 31. 23:52 UTC

Japan's Q2 2026 GDP Growth Rate Expected at 0.3%, Sparking Speculation of Interest Rate Hike Amid Mixed Economic Sentiment

2026. aug. 31. 23:52 UTC

Japan's Q2 2026 GDP Growth Release Expected at 1.1% Amid Mixed Economic Signals and Potential BoJ Interest Rate Hikes

2026. aug. 31. 23:51 UTC

Enterprise Financial Services Corp shares are lower in after-market trading, lacking any specific news to explain the decline. The stock remains below its 20-day moving average.

2026. aug. 31. 23:51 UTC

Dyadic International Inc shares are higher in after-market hours, showing strong buying interest despite a recent significant decline and downward pressure over the past sessions.

2026. aug. 31. 23:51 UTC

Wayfair Inc shares are lower in after-market trading, reversing a trend of higher daily closes. No specific news was identified to explain the decline.

2026. aug. 31. 23:51 UTC

United Parks & Resorts Inc. shares are higher in after-market trading, reflecting notable strength despite no specific company news identified.

2026. aug. 31. 23:51 UTC

Playtika Holding Corp shares are higher in after-market trading. No specific news was identified to explain this movement amid broader market volatility.

2026. aug. 31. 23:51 UTC

European equity markets decline amid rising oil prices and inflation concerns following U.S.-Iran military tensions, with investors cautious ahead of key economic data.

2026. aug. 31. 23:51 UTC

U.S. equity indices decline amid rising oil prices and geopolitical tensions, with Fed rate hike expectations intensifying.

2026. aug. 31. 23:51 UTC

Asia equity markets mixed as Middle East tensions and hawkish Fed signals drive oil prices up and investor caution.

2026. aug. 31. 23:51 UTC

U.S. and European markets decline amid rising oil prices and inflation fears following U.S.-Iran tensions, while Dallas Fed Manufacturing Index signals strong recovery.

2026. aug. 31. 23:51 UTC

Helmerich and Payne Inc. shares are higher in after-market trading, supported by a rise in Brent crude futures amid geopolitical tensions in the Strait of Hormuz.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

132.37% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  132.37%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat